Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base
Included In Small-Cell Lung Cancer Guidelines In US For Second-Line Use
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
You may also be interested in...
The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Keeping Track: US FDA Approvals Include Novel Agents Zepzelca And Uplizna, Biosimilar Nyvepria, Follow-On Semglee
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.